Ingested formula components arrive intact to intestinal villi, thanks to the protection of the enteric layer and from there go into the bloodstream to be selectively incorporated by the cells via various means of cellular transport, depending on the size of molecules such components. Large molecules are incorporated by endocytosis and the smaller molecules are incorporated by simple diffusion or diffusion provided by receptor proteins, as appropriate.
The useful parts of the cell extracts are recycled and used in cells. The parts that are not useful are eliminated and expelled outside the cell.
The incorporation of the various components to the corresponding cell tissues is facilitated by the empathy developed by Biocell Laboratories between these components and the receptor proteins on the cell membrane surface.
Ligand Pharmaceuticals has patents filed for the manufacture and therapeutic use of certain compounds occupying several stated chemical structures, which are intended for use as selective androgen receptor modulators. The patent is filed under the following designations: US8519158 B2, US8865918, US9359285, US20070254875, US20140005186, US20150099720, and WO2005090282A1. The patents will expire on March 12, 2025. These patents effectively protect any future capitalization upon VK5211 in the market by Viking and Ligand through their licensing agreement. 
The Mesterolone hormone is not estrogenic. It does not aromatize and it carries no progestin nature. As a result, the side effects of Proviron will not include any related effects such as gynecomastia or excess water retention. Such adverse effects are impossible with this steroid. This will also greatly reduce the risk of high blood pressure as high blood pressure associated with anabolic steroid use is often due to extreme water retention. In fact, Proviron should provide an anti-estrogenic effect by preventing testosterone to estrogen conversion or at least tremendously slow it down.